A defect of amphiregulin release predicted longer survival independently of YAP expression in patients with pleural mesothelioma in the IFCT-0701 MAPS phase 3 trial.

"CONFLICT OF INTEREST Valérie Gounant reports personal fees from MSD, Chugai, Novartis and Boehringer; personal fees and nonfinancial support from Astra Zeneca, BMS, Takeda and Pfizer; grants, personal fees and nonfinancial support from Roche, all outside the submitted work. Hervé Lena is a Roche board expert, but outside the submitted work. Denis Moro‐Sibilot reports lectures for BMS, MSD, Roche, Astrazeneca, research grant from BMS, MSD, Roche, Astrazeneca and consulting for BMS, MSD, Roche and Astrazeneca, all outside the submitted work. Arnaud Scherpereel participated to expert's boards with BMS, MSD, Astrazeneca and Roche. His institution (CHU of Lille, France) received funding for research studies and clinical trials from BMS, Astrazeneca, MSD and Roche, all outside the submitted work. Gérard Zalcman is the principal investigator of the MAPS trial sponsored by the French Intergroup (IFCT) with a research grant to IFCT for funding ancillary studies from Roche, France. The other authors declare that they have no conflict of interest."

"Funding information The Bio‐MAPS study was sponsored by the Intergroupe Francophone de Cancérologie Thoracique (IFCT), and funded by an unrestricted research grant from ROCHE‐France, research grants from ROCHE‐France (2013) and from the Fond de Recherche en Santé Respiratoire (FRSR, 2012) to Guénaëlle Levallet, a research grant “APRI” from Caen University Hospital for S. Brosseau (2014), and a research grant from the Normandie League against cancer for G. Zalcman (2012)."